Eliezer Masliah, former head of NIA's Neuroscience Division, faces allegations of extensive scientific fraud spanning decades, involving manipulated images in over 132 papers. This scandal impacts drug discoveries like prasinezumab and minzasolmin, raising concerns about the integrity of neurodegenerative disease research.